Details for New Drug Application (NDA): 020259
✉ Email this page to a colleague
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
Summary for 020259
Tradename: | MEPRON |
Applicant: | Glaxosmithkline Llc |
Ingredient: | atovaquone |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020259
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Nov 25, 1992 | TE: | RLD: | Yes |
Expired US Patents for NDA 020259
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Try for Free | ⤷ Try for Free |
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Try for Free | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription